Loading
A phase 2 trial of Cemiplimab in non-small-cell lung cancer, run by Maia Biotechnology, active and no longer recruiting.
THIO Sequenced With Cemiplimab in Advanced NSCLC is a phase 2 interventional study registered as NCT05208944 by Maia Biotechnology, with 227 participants enrolled, started 2022-06-08 and due to reach its primary completion in 2027-09-30. Interventions recorded: 6-Thio-2'-Deoxyguanosine and Cemiplimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Maia Biotechnology, Cemiplimab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Cemiplimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Cemiplimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Cemiplimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Cemiplimab and the tag pipeline.
Shares Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/